Filing Details

Accession Number:
0001104659-23-004744
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-18 20:24:37
Reporting Period:
2023-01-13
Accepted Time:
2023-01-18 20:24:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1442836 Mersana Therapeutics Inc. MRSN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1347582 Anna Protopapas C/O Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge MA 02139
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-05-20 240,244 $0.00 10,371 No 5 G Direct
Common Stock Acquisiton 2022-05-20 240,244 $0.00 240,244 No 5 G Indirect By Trust
Common Stock Acquisiton 2023-01-14 16,750 $0.00 27,121 No 4 M Direct
Common Stock Acquisiton 2023-01-15 21,250 $0.00 48,371 No 4 M Direct
Common Stock Acquisiton 2023-01-15 17,708 $0.00 66,079 No 4 M Direct
Common Stock Disposition 2023-01-17 17,346 $5.74 48,733 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Indirect By Trust
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Acquisiton 2023-01-13 562,500 $0.00 562,500 $6.06
Common Stock Restricted stock unit Acquisiton 2023-01-13 125,000 $0.00 125,000 $0.00
Common Stock Restricted stock unit Disposition 2023-01-14 16,750 $0.00 16,750 $0.00
Common Stock Restricted stock unit Disposition 2023-01-15 21,250 $0.00 21,250 $0.00
Common Stock Restricted stock unit Disposition 2023-01-15 17,708 $0.00 17,708 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
562,500 2033-01-12 No 4 A Direct
125,000 No 4 A Direct
50,250 No 4 M Direct
42,500 No 4 M Direct
17,708 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 72,263 Indirect By Trust
Footnotes
  1. These shares of common stock are held by the Anna Protopapas Irrevocable Trust (the "Protopapas Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse is the trustee of the Protopapas Trust.
  2. Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.
  3. Represents shares of common stock received upon the vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2021.
  4. Represents shares of common stock received upon the vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2020.
  5. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs reported above. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
  6. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  7. These shares of common stock are held by the Kinney/Protopapas Family Irrevocable Trust (the "Kinney/Protopapas Trust") for the benefit of the Reporting Person's children. The Reporting Person's spouse is a co-trustee of the Kinney/Protopapas Trust.
  8. The option shall vest in equal quarterly installments over four years from the date of grant.
  9. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
  10. The RSUs shall vest in equal annual installments over four years from the date of grant.
  11. 25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.
  12. 25% of the total number of RSUs granted vested on January 15, 2023, and the remainder shall vest thereafter in equal annual installments over the next two years.
  13. 25% of the total number of RSUs granted vested on January 15, 2023, and the remainder shall vest on January 15, 2024.